Company intelligence / Profile preview

Debra

Munich, Germanydebra-international.org ↗

Ownership: Private
Development stage: Other

Overview

DEBRA Research is a non-profit research arm of DEBRA Austria dedicated to advancing research and developing new treatments for Epidermolysis Bullosa. It operates globally to convert scientific discoveries into practical therapies. In 2025, it announced a strategic partnership with LEO Pharma to accelerate development of life-changing medicines for EB patients. There are currently no approved treatments or cures for EB.

Therapeutic areas: Dermatology
Modalities: small moleculesbiologicsgene therapy
Industry: Academic Hospital/University/Research

Partnerships

LEO Pharma

Beyond the preview

Go deeper on Debra.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Debra.

Explore the full profile